Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein

Area of Science:

• Oncology
• Molecular Biology
• Bioinformatics

Background:

• Deregulation of the von Hippel-Lindau tumor suppressor protein (pVHL) is a key factor in renal clear-cell carcinoma (ccRCC) development.
• pVHL exists as two isoforms, pVHL19 and pVHL30, with potential differences in tumor suppression.
• p53 gene mutations are linked to ccRCC, and pVHL30 interacts with p53 pathway regulators like p14ARF.

Purpose of the Study:

• To investigate the distinct structural and binding properties of pVHL19 and pVHL30 isoforms.
• To elucidate the specific interactions mediated by each pVHL isoform in the context of ccRCC.
• To characterize the functional asymmetry between pVHL19 and pVHL30.

Main Methods:

• Integrative bioinformatics analysis, including 3D structure prediction of the pVHL30 N-terminus.
• Experimental validation using Yeast two-hybrid assays to assess isoform-specific binding.
• Characterization of pVHL/p14ARF interactions and pVHL isoform homodimerization.

Main Results:

• The pVHL30 N-terminus, comprising 53 residues, is crucial for physical interaction with p14ARF.
• pVHL19, lacking the N-terminal 53 residues, does not interact with p14ARF.
• pVHL19 exhibits a significant propensity for homodimerization, distinct from pVHL30.
• pVHL30's N-terminus may exist as a dynamic ensemble of structured and disordered forms.

Conclusions:

• The N-terminal region of pVHL30 serves as a specific interaction interface for p14ARF, mediating a key aspect of pVHL's tumor suppressor function.
• The pVHL19 isoform possesses unique binding specialization through homodimerization, suggesting distinct roles in ccRCC.
• These findings highlight isoform-specific functions of pVHL in ccRCC pathogenesis and offer potential therapeutic targets.